Enanta Pharmaceuticals, Inc. (ENTA)
$51.51
+0.02 (+0.04%)
Rating:
Recommendation:
Buy
| Symbol | ENTA |
|---|---|
| Price | $51.51 |
| Beta | 0.355 |
| Volume Avg. | 0.17M |
| Market Cap | 1.076B |
| Shares () | - |
| 52 Week Range | 37.59-79.495 |
| 1y Target Est | - |
| DCF Unlevered | ENTA DCF -> | |
|---|---|---|
| DCF Levered | ENTA LDCF -> | |
| ROE | -34.73% | Strong Sell |
| ROA | -32.43% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 16.83% | Neutral |
| P/E | - | |
| P/B | 3.30 | Strong Buy |
Latest ENTA news
About
Download (Excel)Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.